Compare AstraZeneca plc (AZN) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Johnson Controls International PLC — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Johnson Controls International PLC trades at $155.05 (market cap $93.74B). The key difference: AstraZeneca plc is far larger — about 2.6× Johnson Controls International PLC's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | JCI | |
|---|---|---|
Market Cap | $248.14B | $93.74B |
Sector | Health | Industrials |
52-Week High | $209.48 | $154.76 |
52-Week Low | $147.06 | $103.52 |
Enterprise Value | $275.41B | $102.58B |
Dividend Yield | 2.01% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
JCI trades at $153.59, up 1.92% on the day, with a bullish technical outlook and strong institutional support. Recent Q3 2026 earnings beat expectations with $1.42 EPS versus $1.30 expected, driven by double-digit organic growth in data-center thermal systems. The company raised FY26 guidance, reflecting robust demand and operational momentum. Valuation ratios remain elevated, with a P/E of 43.59 and P/S of 3.82, indicating premium pricing relative to historical norms.
The outlook is positive, supported by earnings momentum and AI-driven demand for cooling solutions, but risks include high valuation sensitivity and debt levels. Analyst consensus price target is $168.25, suggesting ~9.5% upside, with no sell ratings among 45 analysts. Investors should monitor execution on guidance and macroeconomic impacts on construction and HVAC markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
